Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI body scans could make chemo safer for women with ovarian and endometrial cancer

NCT ID NCT07144618

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether using an AI tool to analyze a patient's body composition from a CT scan can help doctors personalize chemotherapy dosing. The goal is to reduce severe side effects like low white blood cell counts in women with endometrial or ovarian cancer. About 294 participants will be randomly assigned to receive either standard dosing or AI-assisted dosing, and researchers will compare side effects, quality of life, and survival rates.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Paclitaxel (chemotherapy)
What this could lead to
If successful, this could lead to a more personalized way to dose chemotherapy, reducing severe side effects like low white blood cell counts and improving quality of life for patients.
What could go wrong
This is an early-stage study (Phase NA) with 294 participants, so results may not apply to all patients. The AI tool's predictions might not consistently outperform standard dosing, and the study focuses on specific cancers and chemotherapy drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 294 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Able to comprehend and willing to participate in this clinical trial, with signed informed consent. 2. Underwent an abdominal computed tomography (CT) scan within three months prior to surgical treatment, with a non-contrast-enhanced single-slice image at the third lumbar vertebral level available for body composition analysis. 3. Histologically or cytologically confirmed diagnosis of endometrial cancer or ovarian cancer. 4. Age between 20 and 80 years. 5. Good performance status (ECOG performance status of 0, 1, or 2). 6. Adequate hematologic parameters: * Hemoglobin ≥10 g/dL * White blood cell count ≥3,000/μL * Neutrophil count ≥1,500/μL * Platelet count ≥100,000/μL 7. Adequate organ function: * Total bilirubin ≤1.5 times the upper limit of normal (ULN). * Alanine aminotransferase (ALT) / Aspartate aminotransferase (AST) ≤2.5 times ULN (≤5.0 times ULN for patients with liver metastases). * Creatinine ≤ ULN. Exclusion Criteria 1\. Presence of other major diseases that may be exacerbated by chemotherapy (e.g., autoimmune diseases). 2\. History of other malignancies within the past two years before trial enrollment, except for adequately treated non-melanoma skin cancer, stage 0 cervical carcinoma, or ductal carcinoma in situ of the breast. 3\. Requirement for concurrent treatment of unrelated diseases during the trial period, including chemotherapy, radiotherapy, or investigational drugs. 4\. Mental status deemed unsuitable for participation in the clinical trial. 5. Expected survival time of less than six months. 6. Poor-quality abdominal CT images, clearly attributable to the following causes: * Motion artifacts due to poor patient compliance. * Noticeable scoliosis or kyphosis. * Multiple lumbar vertebral compression fractures. * Significant generalized edema. * Presence of metallic implants in the lumbar spine or abdomen. * Abdominal stoma or significant abdominal wall defects. * Marked asymmetry or localized atrophy/deficiency of the core abdominal musculature.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Cheng Kung University Hospital

    Tainan, 704, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.